Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinarybladder in patients with multiple sclerosis
- Authors: Stankovich EY.1, Borisov VV1, Demina TL1
-
Affiliations:
- Issue: No 4 (2004)
- Pages: 48-51
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/275326
- ID: 275326
Cite item
Full Text
Abstract
Urination disorders occur in 80% patients with multiple sclerosis
(MS). Most common of them is detrusor-sphincter dyssynergia
(DSD). Alphal-adrenoblockers can relax the neck of the urinary
bladder (UB) and urethral sphincters, thus eliminating dynamic obstruction,
reducing resistance to urine flow and facilitating voiding.
Our study assessed feasibility of using a selective alpha lA/D-adrenoblocker
tamsulosin in MS-associated DSD. The choice of this alphaadrenoblocker
was based on its high safety profile in relation to cardiovascular
system. The trial enrolled 28 patients (20 females and 8
males) with verified diagnosis of DSD. They were given tamsulosin
(omnik) in a dose 0.4 mg/day (1 capsule) for 2 months. To the end
of the trial quality of life raised in 96% patients. Occurrence of pollakiuria,
number of imperative micturate urges diminished, the IPSS
score decreased by 54%, QL index improved by 58%. There was also
a decrease in the volume of the residual urine, amplitude of involuntary
detrusor contractions, an increase in maximal volumic speed of
urine flow, cystometric volume of the UB, mean urine volume in urination.
Side effects were not registered. Thus, tamsulosin has a positive
effect in voiding disorders in the presence of DSD associated
with MS. This considerably improves quality of life of MS patients.
(MS). Most common of them is detrusor-sphincter dyssynergia
(DSD). Alphal-adrenoblockers can relax the neck of the urinary
bladder (UB) and urethral sphincters, thus eliminating dynamic obstruction,
reducing resistance to urine flow and facilitating voiding.
Our study assessed feasibility of using a selective alpha lA/D-adrenoblocker
tamsulosin in MS-associated DSD. The choice of this alphaadrenoblocker
was based on its high safety profile in relation to cardiovascular
system. The trial enrolled 28 patients (20 females and 8
males) with verified diagnosis of DSD. They were given tamsulosin
(omnik) in a dose 0.4 mg/day (1 capsule) for 2 months. To the end
of the trial quality of life raised in 96% patients. Occurrence of pollakiuria,
number of imperative micturate urges diminished, the IPSS
score decreased by 54%, QL index improved by 58%. There was also
a decrease in the volume of the residual urine, amplitude of involuntary
detrusor contractions, an increase in maximal volumic speed of
urine flow, cystometric volume of the UB, mean urine volume in urination.
Side effects were not registered. Thus, tamsulosin has a positive
effect in voiding disorders in the presence of DSD associated
with MS. This considerably improves quality of life of MS patients.
References
- Goldstein L, Siroky М. В., Sax D. S., Krane R. J. Neurourologic abnormalities in multiple sclerosis. J. Urol. (Baltimore) 1982; 128: 541-545.
- Koldewijn E. L., Hommes O. R., Letomens W. A. J. G. et al. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J. Urol. (Baltimore) 1995; 154: 169-173.
- Bemelmans B. L. H., Hommes O. R., Van Kerrebroeck P. E. V. et al. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J. Urol. (Baltimore) 1991; 145: 1219-1224.
- McGuire E. J., Savastano J. A. Urodynamic findings and longterm outcome management of patients with multiple sclerosisinduced lower urinary tract dysfunction. J. Urol. (Baltimore) 1984; 132: 713-715.
- Chancellor M. B. Detrusor-external sphincter dyssynergia. Ciba Found Symp. 1990; 151: 195-206.
- Goodwin R. J., Fowler С. J. Bladder, bowel and sexual dysfunction: recent advances. In: ThompsonA. J., Polman C, Hohlfeld R., eds. Multiple sclerosis: clinical challenges and controversies. London: Martin Dunitz; 1997. 265-281.
- Мазо Е. Б., Кривобородов Г. Г., Шварц П. Г. Нарушения мочеиспускания у больных рассеянным склерозом. Клиника, диагностика, лечение: Метод, рекомендации. М.; 2001.
- Kunisawa Y. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. J. Urol. (Baltimore) 1985; 134 (2): 396-398.
- Пушкарь Д. Ю., Щавелева О. Б. Медикаментозное лечение императивных расстройств мочеиспускания. Фарматека 2002; 10: 3-8.
- Сивков А. В., Ромих В. В., Егоров А. А. Применение а,-блокаторов при расстройствах мочеиспускания у женщин. Урология 2002; 5, прил.: 52-63.
- Anderson К., Lepor H., Willie M. Prostatic aladrenoreceptor and uroselectivity. Prostate 1997; 30: 202-215.
- Мартов А. Г., Гущин Б. Л., Ощепков В. В., Ергаков Д. В. Применение а,-блокаторов для лечения мочеиспускания у больных после трансуретральной резекции предстательной железы. Урология 2002; 5, прил.: 13-22.
- Beduschi R., Beduschi M., Oessterling J. Benign prostatic hyperplasia: use of drag therapy in primary care. Geriatrics 1998; 53: 24-28.
- Puppo P. Do we know everything about alpha-blokade in the management of lower tract symptoms? Eur. Urol. 2001; 39 (suppi. 2): 38-41.
- Schwinn D. A., Michelotti G. A. a-adrenergic receptors in the lower urinary tract and vascular bed. Br. J. Urol. Int. 2000: 85 (suppl. 2): 6-11.
- Betts С. D., Mellow M. Т., Fowler C. J. Urinary symptoms and neurological features of bladder dysfunction in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1993; 56: 245-250.
- Жирникова М. Л., Винаров A. З., Машковский М. Д., ПытельЮ. А. Блокаторы альфаадренорецепторов в терапии больных аденомой предстательной железы. В кн.: Пленум Всероссийского о-ва урологов. Саратов; 1994. 88-96.
- Кан Я. Д., Вишневский А. Е. Современные принципы медикаментозной терапии доброкачественной гиперплазии простаты. Лечащий врач 1999; 1.
- Лопаткин Н. А., Перепанова Т. С. Клинический опыт лечения больных доброкачественной гиперплазией предстательной железы а,-адреноблокатором альфузодином. Урол. и нефрол. 1997; 5: 14-17.
- Ткачук В. Н., Аль-Шукри С. X., Кузнецова М. И., Торосян О. Р. Тамсулозин в лечении больных хроническим простатитом. Урология 2000; 5: 18-20.
Supplementary files
